Long‐term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through 2 Years: Results from a Phase 3, Randomized, Double‐blind, Placebo‐controlled Study Conducted in Biologic‐naïve Patients with Active Psoriatic Arthritis

Arthritis & Rheumatology ◽

10.1002/art.42010 ◽

2021 ◽

Author(s):

Iain B. McInnes ◽

Proton Rahman ◽

Alice B. Gottlieb ◽

Elizabeth C. Hsia ◽

Alexa P. Kollmeier ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Term Efficacy ◽

Interleukin 23

Download Full-text

228. Secukinumab, A Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicentre, Double-Blind, Placebo-Controlled Study

Rheumatology ◽

10.1093/rheumatology/kev089.115 ◽

2015 ◽

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Radiographic Progression ◽

Safety Data ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 17A

Download Full-text

Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study

The Journal of Dermatology ◽

10.1111/1346-8138.14504 ◽

2018 ◽

Vol 45 (9) ◽

pp. 1053-1062 ◽

Cited By ~ 31

Author(s):

Mamitaro Ohtsuki ◽

Hiroshi Kubo ◽

Hitomi Morishima ◽

Ryosuke Goto ◽

Richuan Zheng ◽

...

Keyword(s):

Monoclonal Antibody ◽

Japanese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Plaque Type ◽

Interleukin 23

Download Full-text

OP0234 EFFICACY AND SAFETY OF BRODALUMAB, AN ANTI-INTERLEUKIN-17 RECEPTOR A MONOCLONAL ANTIBODY, IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A 16 WEEK RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

10.1136/annrheumdis-2019-eular.6888 ◽

2019 ◽

Cited By ~ 2

Author(s):

James Cheng-Chung Wei ◽

Tae-Hwan Kim ◽

Mitsumasa Kishimoto ◽

Takuya Morishige ◽

Naoki Ogusu ◽

...

Keyword(s):

Monoclonal Antibody ◽

Axial Spondyloarthritis ◽

Controlled Study ◽

Interleukin 17 ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

OP0218 Efficacy and safety results of guselkumab, an anti-il23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: a phase 2a, randomized, double-blind, placebo-controlled study

10.1136/annrheumdis-2017-eular.1164 ◽

2017 ◽

Cited By ~ 6

Author(s):

A Deodhar ◽

A Gottlieb ◽

W-H Boehncke ◽

B Dong ◽

Y Wang ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study

Diabetes Care ◽

10.2337/dc12-0706 ◽

2012 ◽

Vol 36 (2) ◽

pp. 237-244 ◽

Cited By ~ 120

Author(s):

J. B. McGill ◽

L. Sloan ◽

J. Newman ◽

S. Patel ◽

C. Sauce ◽

...

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Severe Renal Impairment ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Term Efficacy

Download Full-text

A multi-center, double-blind, placebo-controlled study of the long-term efficacy and safety of acarbose (BAYg 5421) in the treatment of obese patients with NIDDM treated by diet alone

New Aspects in Diabetes ◽

10.1515/9783110859447-020 ◽

1992 ◽

pp. 233-233

Author(s):

R. F. Coniff

Keyword(s):

Controlled Study ◽

Obese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Term Efficacy

Download Full-text

Faculty Opinions recommendation of Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717961956.793465689 ◽

2012 ◽

Author(s):

Pierre Ronco ◽

Jean-Jacques Boffa

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Severe Renal Impairment ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Term Efficacy

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718257967.793494565 ◽

2014 ◽

Author(s):

Christian Jorgensen ◽

Yves-Marie Pers

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

OP0174 Efficacy and Safety of Ustekinumab in Psoriatic Arthritis Patients with Spondylitis and Peripheral Joint Involvement: Results from a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.3096 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 136.1-136 ◽

Cited By ~ 3

Author(s):

A. Kavanaugh ◽

L. Puig ◽

A.B. Gottlieb ◽

C. Ritchlin ◽

Y. You ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Study ◽

Joint Involvement ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Results of A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy And Safety of Sirukumab, An Anti-IL-6 Cytokine Monoclonal Antibody, In Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment (Sirround-D)

Value in Health ◽

10.1016/j.jval.2016.09.1074 ◽

2016 ◽

Vol 19 (7) ◽

pp. A531 ◽

Cited By ~ 2

Author(s):

T Takeuchi ◽

C Thorne ◽

G Karpouzas ◽

S Sheng ◽

W Xu ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Rheumatic Drug

Download Full-text